Novabay Pharmaceuticals Inc P / E
Was ist das P / E von Novabay Pharmaceuticals Inc?
P / E von Novabay Pharmaceuticals Inc ist 0.00
Was ist die Definition von P / E?
Das Terminkurs-Gewinn-Verhältnis ist das Verhältnis des Aktienkurses eines Unternehmens zum geschätzten Gewinn des Unternehmens je Aktie für die nächsten zwölf Monate.
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P / E von Unternehmen in Health Care Sektor auf NYSEMKT im Vergleich zu Novabay Pharmaceuticals Inc
Was macht Novabay Pharmaceuticals Inc?
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Unternehmen mit p / e ähnlich Novabay Pharmaceuticals Inc
- Richland Resources International hat P / E von N/A
- Safeplus International hat P / E von N/A
- China Yanyuan Yuhui Natl Ed Grp hat P / E von N/A
- Acusphere hat P / E von N/A
- American Oriental Bioengineering hat P / E von N/A
- Gourmet Provisions International hat P / E von N/A
- Novabay Pharmaceuticals Inc hat P / E von 0.00
- SEL Manufacturing hat P / E von 0.00
- China Zhong Qi Hldgs hat P / E von 0.00
- MedSmart hat P / E von 0.00
- Panbela Therapeutics hat P / E von 0.00
- Epic hat P / E von 0.00
- 2574 hat P / E von 0.00